BBIO Jan 2026 40.000 call
| Previous close | 9.50 |
| Open | 9.50 |
| Bid | 3.60 |
| Ask | 7.40 |
| Strike | 40.00 |
| Expiry date | 2026-01-16 |
| Day's range | 9.50 - 9.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 65 |
GlobeNewswireBridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” pa
Investor's Business DailyBridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
BridgeBio stock gave up gains midday Tuesday after releasing a Phase 2 study on a growth disorder treatment.
- GlobeNewswire
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.50 cm/yr at Month 18 (p=0.0015) - At Month 18, there was a statistically significant improvement in body proportionality (p-value of 0.001). The mean upper to lower body segment ratio was 1.88 at Month 18, as compared to 2.02 at baseline - Infigratinib con
